Celularity CELU

Celularity Inc is a cellular and regenerative medicine company focused on advancing health longevity by developing off‑the‑shelf placental‑derived allogeneic cell therapies and biomaterial products. The company sources post‑partum human placenta to manufacture natural killer cells, mesenchymal‑like stromal cells and a range of tissue‑based allografts that target age‑related degeneration, immune dysfunction and wound repair. Its operations are centered in a purpose‑built, cGMP‑compliant facility in Florham Park, New Jersey, where it integrates biobanking, manufacturing and research activities.

Celularity generates revenue primarily through the sale of its commercial biomaterial products such as Biovance®, Biovance® 3L, Interfyl® and Rebound™ to hospitals, surgical centers and wound‑care providers. It also collects fees from its biobanking service for the collection, processing and long‑term storage of umbilical cord blood and placental tissue for expectant parents. Additionally, the company earns income by providing contract manufacturing and development services to third‑party biopharma firms that wish to leverage its placental‑cell expertise and scalable production capabilities.

The company operates through the following segments:

• Degenerative Disease: This segment includes the development and sale of advanced biomaterial products for wound care and the treatment of degenerative conditions, such as Biovance® 3L, Interfyl®, Rebound™ and investigational products like the Celularity Tendon Wrap, Fuse Bone Void Filler and Placental Membrane.

• Advanced Biomaterial Products: This segment covers the commercial‑stage allograft and connective‑tissue matrix offerings, including Biovance®, Biovance® 3L and Interfyl®, which are marketed directly or through distribution partners for soft‑tissue repair and reconstructive procedures.

Celularity occupies a niche within the regenerative medicine industry by leveraging the immunological naiveté, high proliferative capacity and scalability of placenta‑derived cells, which differentiates it from many adult‑cell‑based competitors. Key rivals in the allogeneic natural killer cell space include Fate Therapeutics, Century Therapeutics, Nkarta, Artiva Biotherapeutics, Wugen and Shoreline Biosciences, while competitors in the mesenchymal stromal cell arena comprise Mesoblast and Longeveron. The company’s competitive advantages stem from its proprietary IMPACT platform that enables end‑to‑end, cost‑effective manufacturing, its ability to produce off‑the‑shelf products at scale, and its extensive intellectual property portfolio covering placental‑cell processing and therapeutic applications.

The company serves a diverse customer base that includes hospitals, ambulatory surgical centers, wound‑care clinics and physicians who use its biomaterial products for surgical and regenerative procedures. Expectant parents constitute the clientele for its fee‑based biobanking service. Third‑party biopharma and biotechnology companies utilize its contract manufacturing and development offerings. Specific partners disclosed in the filing are BioCellgraft, Inc., which distributes private‑label biomaterial products in the dental and oral‑health market, and Defeye, Inc., with which Celularity collaborates on ophthalmic biomaterial applications.